Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008

OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

Cannabinoid receptors in human astroglial tumors.

Authors: Janka Held‐Feindt, Lutz Dörner, Gülcan Sahan,H. Maximilian Mehdorn, Rolf Mentlein
Journal of Neurochemistry, August 2008

In animal models, cannabinoids are reported to inhibit the growth of tumors, including gliomas. These effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, we investigated recept…

Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development.

Authors: Ester Fride
Journal of Neuroendocrinology, May 2008

The endocannabinoid system, including its receptors (CB(1) and CB(2)), endogenous ligands (‘endocannabinoids’), synthesising and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and pos…

Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis.

Authors: Denise Richardson, Richard G. Pearson, Nisha Kurian, M. Liaque Latif, Michael J. Garle, et al
Arthritis Research & Therapy, April 2008

INTRODUCTION: Cannabis-based medicines have a number of therapeutic indications, including anti-inflammatory and analgesic effects. The endocannabinoid receptor system, including the cannabinoid receptor 1 (CB1) and receptor 2 (CB2) and the endocannabinoids, are implicated in…

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008

OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.

Authors: Vincent Maida, Marguerite Ennis, Shiraz Irani, Mario Corbo, Michael Dolzhykov
Journal of Supportive Oncology, March 2008

A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days’ follow-up, in…

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors: Mark A Ware, Paul Daeninck, Vincent Maida
Therapeutics and Clinical Risk Management, February 2008

Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a significant burden on patients’ function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients expe…

Association of the cannabinoid receptor gene (CNR1) with ADHD and post‐traumatic stress disorder.

Authors: Ake T. Lu, Matthew N. Ogdie, Marjo‐Ritta Järvelin, Irma K. Moilanen, Sandra K. Loo, et al
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 22 January 2008

Attention deficit hyperactivity disorder (ADHD) is a highly heritable disorder affecting some 5-10% of children and 4-5% of adults. The cannabinoid receptor gene (CNR1) is a positional candidate gene due to its location near an identified ADHD linkage peak on chromosome 6, its…

Cannabinoids for cancer treatment: progress and promise.

Authors: Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, Hasan Mukhtar
Cancer Research, 15 January 2008

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of…

Marijuana dependence and its treatment.

Authors: Alan J. Budney, Roger Roffman, Robert S. Stephens, Denise Walker
Addiction Science & Clinical Practice, December 2007

The prevalence of marijuana abuse and dependence disorders has been increasing among adults and adolescents in the United States. This paper reviews the problems associated with marijuana use, including unique characteristics of marijuana dependence, and the results of laborat…

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

Authors: Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia, Pierre-Yves Desprez
Molecular Cancer Therapeutics, November 2007

Invasion and metastasis of aggressive breast cancer cells is the final and fatal step during cancer progression, and is the least understood genetically. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Clear…

Fitness to drive in spite (because) of THC.

Authors: Peter Strohbeck-Kühner, Gisela Skopp, Rainer Mattern
Archiv für Kriminologie, July-August 2007

Attention-deficit/hyperactivity disorder (ADHD) is characterized by a lack of concentration and/or an altered activation level. People with ADHD are found to violate traffic regulations, to commit criminal offences and to be involved in traffic accidents more often than the st…